🆕Endometrial cancer treatment recommended by NICE Dostarlimab, recommended in final guidance, is set to benefit around 570 people with certain types of primary advanced or recurrent endometrial cancer. Clinical trials show that adding dostarlimab to standard chemotherapy helps women stay well longer⤵️ https://www.nice.org.uk/guidance/ta1064?utm_medium=organic&utm_source=whatsapp&utm_campaign=dostarlimab_220525&utm_content=finalvideo